Tools
Tools
Henney, N, Banach, M and Penson, P (2021) RNA Silencing in the Management of Dyslipidemias. Current Atherosclerosis Reports. ISSN 1523-3804
|
Text
RNA Silencing in the Management of Dyslipidemias.pdf - Published Version Available under License Creative Commons Attribution. Download (954kB) | Preview |
Abstract
Purpose of Review Remarkable reductions in cardiovascular morbidity and mortality have been achieved in recent decades through the widespread use of ‘small-molecule’ hypolipidaemic drugs such as statins and ezetimibe. An alternative approach is to perturb the production of proteins through ribonucleic acid (RNA) silencing, leading to long-lasting knock-down of specific biological molecules. This review describes the scientific basis of RNA silencing, and critically evaluates the evidence relating to inclisiran, a small interfering RNA against proprotein convertase subtilisin kexin 9 (PCSK9).
Recent Findings Pooled analysis of three recent ORION trials has demonstrated that twice-yearly administration of inclisiran reduces LDL-C by 50% in a range of patient groups, with only mild adverse effects.
Summary Inclisiran provides safe, effective and long-lasting reductions in PCSK9 and LDL-C. The results of the phase-3 ORION-4 outcomes study are eagerly awaited. Further promising RNA silencing technologies have the potential to improve the management of dyslipidaemia.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | 1102 Cardiorespiratory Medicine and Haematology |
| Subjects: | Q Science > QD Chemistry Q Science > QH Natural history > QH301 Biology Q Science > QH Natural history > QH426 Genetics R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Pharmacy & Biomolecular Sciences |
| Publisher: | Springer |
| Date Deposited: | 02 Sep 2021 09:21 |
| Last Modified: | 04 Sep 2021 05:05 |
| DOI or ID number: | 10.1007/s11883-021-00968-7 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/15430 |
 |
View Item |